Why Shares of Surmodics Jumped This Week
The company gained FDA marketing approval for a drug-coated balloon that will help clear blocked arteries.
Why Shares of Surmodics Soared on Tuesday
An analyst upgrade gave the stock a boost.
Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised
Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 18.37% and 4.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March...